Avid Radiopharms Inc Drug Patent Portfolio

Avid Radiopharms Inc owns 2 orange book drugs protected by 3 US patents Given below is the list of Avid Radiopharms Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8932557 Imaging agents for detecting neurological dysfunction 26 May, 2032
Active
US7687052 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques 30 Apr, 2027
Active
US8506929 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques 30 Apr, 2027
Active


Given below is the list of recent legal activities going on the following drug patents of Avid Radiopharms Inc.

Activity Date Patent Number
Patent litigations
Patent Term Extension Certificate 18 Oct, 2023 US8932557
Notice of Final Determination -Eligible 01 Sep, 2023 US8932557
FDA Final Eligibility Letter 26 Apr, 2023 US8932557
transaction for FDA Determination of Regulatory Review Period 30 Jun, 2022 US8932557
Payment of Maintenance Fee, 8th Year, Large Entity 22 Jun, 2022 US8932557
Second letter to regulating agency to determine regulatory review period 05 Nov, 2021 US8932557
Payment of Maintenance Fee, 12th Year, Large Entity 30 Sep, 2021 US7687052 (Litigated)
Payment of Maintenance Fee, 8th Year, Large Entity 15 Feb, 2021 US8506929
Letter from FDA or Dept of Agriculture re PTE application 14 Dec, 2020 US8932557
Initial letter Re: PTE Application to regulating agency 05 Nov, 2020 US8932557
Patent Term Extension Application under 35 USC 156 Filed 28 Aug, 2020 US8932557
Patent Term Extension Application under 35 USC 156 Filed 16 Jul, 2020 US8932557
Post Issue Communication - Certificate of Correction 05 Jul, 2019 US7687052 (Litigated)
Post Issue Communication - Certificate of Correction 02 Jul, 2019 US8506929
Post Issue Communication - Certificate of Correction 25 Mar, 2019 US8506929


Avid Radiopharms Inc Drug Patents' Oppositions Filed in EPO

Avid Radiopharms Inc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 31, 2022, by Life Molecular Imaging Ltd.. This opposition was filed on patent number EP09711194A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP09711194A Oct, 2022 Life Molecular Imaging Ltd. Granted and Under Opposition


Avid Radiopharms Inc's Family Patents

Avid Radiopharms Inc drugs have patent protection in a total of 33 countries. It's US patent count contributes only to 16.7% of its total global patent coverage. 5 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Avid Radiopharms Inc Drug List

Given below is the complete list of Avid Radiopharms Inc's drugs and the patents protecting them.


1. Amyvid

Amyvid is protected by 2 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7687052 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques 30 Apr, 2027
(2 years from now)
Active
US8506929 Styrylpyridine derivatives and their use for binding and imaging amyloid plaques 30 Apr, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Amyvid's drug page


2. Tauvid

Tauvid is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8932557 Imaging agents for detecting neurological dysfunction 26 May, 2032
(7 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Tauvid's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List